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Abstract
Ductal carcinoma in situ (DCIS) is a noninvasive precursor lesion to invasive breast carcinoma. 
We still have no understanding on why only some DCIS lesions evolve to invasive cancer whereas 
others appear not to do so during the life span of the patient. Here, we performed full exome 
(tumor vs. matching normal), transcriptome, and methylome analysis of 30 pure high-grade DCIS 
(HG-DCIS) and 10 normal breast epithelial samples. Sixty-two percent of HG-DCIS cases 
displayed mutations affecting cancer driver genes or potential drivers. Mutations were observed 
affecting PIK3CA (21% of cases), TP53 (17%), GATA3 (7%), MLL3 (7%) and single cases of 
mutations affecting CDH1, MAP2K4, TBX3, NF1, ATM, and ARID1A. Significantly, 83% of 
lesions displayed numerous large chromosomal copy number alterations, suggesting they might 
precede selection of cancer driver mutations. Integrated pathway-based modeling analysis of 
RNA-seq data allowed us to identify two DCIS subgroups (DCIS-C1 and DCIS-C2) based on their 
tumor-intrinsic subtypes, proliferative, immune scores, and in the activity of specific signaling 
pathways. The more aggressive DCIS-C1 (highly proliferative, basal-like, or ERBB2+) displayed 
signatures characteristic of activated Treg cells (CD4+/CD25+/FOXP3+) and CTLA4+/CD86+ 
complexes indicative of a tumor-associated immunosuppressive phenotype. Strikingly, all lesions 
showed evidence of TP53 pathway inactivation. Similarly, ncRNA and methylation profiles 
reproduce changes observed postinvasion. Among the most significant findings, we observed 
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upregulation of lncRNA HOTAIR in DCIS-C1 lesions and hypermethylation of HOXA5 and SOX 
genes. We conclude that most HG-DCIS lesions, in spite of representing a preinvasive stage of 
tumor progression, displayed molecular profiles indistinguishable from invasive breast cancer.
Introduction
Ductal carcinoma in situ (DCIS) is by definition a precursor lesion to invasive ductal 
carcinoma (IDC). The routine use of screening mammography has led to a dramatic increase 
in DCIS detection during the last four decades (1). More than 62,000 cases per year account 
for about 25% of new breast cancers in the United States (1). Early retrospective studies 
concluded that women with biopsy proven DCIS have over a 10-fold higher risk for 
developing invasive carcinoma than women without DCIS history (2). If left untreated, it 
has been estimated that at least one-third of DCIS cases are likely to progress to IDC during 
the lifetime of the patient (1, 3). Regardless, it is beyond debate that the vast majority of 
IDCs results from the progression of precursor DCIS lesions (3). DCIS lesions are usually 
classified as either high-grade (HG-DCIS) or low-grade (LG-DCIS). Such distinction has 
limited impact on clinical management, as most patients with DCIS regardless of grade still 
receive similar treatment, which is either total mastectomy or segmental resection with 
radiation therapy (4–6). Recent studies argued that it is possible to identify more indolent 
DCIS lesions based on a small gene expression panel (Oncotype DX DCIS; ref. 7); however, 
concerns have been raised on the usefulness of such test and further validation is required (8, 
9). Nevertheless, there is a great clinical need to identify those patients who can be spared 
radiation therapy after segmental resection, as it has been argued that many patients do not 
benefit from this likely overtreatment (10, 11).
Our current understanding of DCIS is that these are heterogeneous lesions and just like 
invasive carcinoma, DCIS lesions can be separated into different intrinsic subtypes on the 
basis of gene expression features (12–15). Mutations affecting genes such as TP53 and 
PIK3CA were also reported in DCIS (16, 17). However, as reviewed by Polyak, molecular 
signatures predictive of invasive progression have not been defined (18). In other words, we 
still have no understanding on why only some DCIS lesions evolve to invasive cancer 
whereas others appear not to do so. Importantly, no study to date has comprehensively 
delineated the molecular landscape of DCIS at the mutational, transcriptomic, and epigenetic 
levels in the same lesions and these are in part major goals of the present study.
Materials and Methods
Samples
Thirty fresh-frozen pure HG-DCIS cases with matched normal adjacent breast tissue 
samples were obtained from the MDACC Breast Tumor Bank. Normal breast tissue is 
defined as grossly unremarkable breast parenchyma away from the area of DCIS identified 
by imaging studies and gross evaluation and confirmed by subsequent histologic evaluation. 
These areas usually selected at least 1 cm and more away from the lesions. Patient tissue 
samples were collected after proper informed consents were obtained and protocols 
approved by ethical and institutional review boards. Ten cosmetic normal mammoplasty 
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specimens were obtained from the Cooperative Human Tissue Network. Normal breast 
epithelial organoids were freshly isolated from the normal mammoplasty specimens as was 
previously described by us (19) and used for identification of differentially expressed genes 
(DEG) and differentially methylated genes (DMG) between normal and HG-DCIS samples.
DNA from 29 of 30 (97%) pure HG-DCIS samples and their paired normal breast tissue 
samples (total 58 samples) were subjected to exome capture sequencing analysis (Exome-
Seq). DNA from 24 of 30 (80%) HG-DCIS samples and 5 normal breast organoids (total 29 
samples) were subjected to reduced representation bisulfite sequencing analysis (RRBS). 
RNAs from 25 of 30 (83%) pure HG-DCIS and 10 normal breast organoids (total 35 
samples) were subjected to RNA sequencing analysis (RNASeq; see Supplementary Table 
S1).
Histopathologic and immunohistochemical analysis
Histopathologic analysis of tumors and lymphocytic infiltrates were performed on 
hematoxylin and eosin (H&E)-stained sections. Intratumor-infiltrating lymphocytes (iTIL) 
are defined as intraepithelial mononuclear cells within DCIS cell nests or in direct contact 
with cells (intralobular stroma) and are reported as the percentage of the tumor epithelial 
nests that contain infiltrating lymphocytes. Stromal tumor-infiltrating lymphocytes (sTIL) 
are defined as the percentage of tumor stroma area that contains lymphocytic infiltrates 
without direct contact to DCIS cells. All samples were analyzed for estrogen receptor (ER)/
progesterone receptor (PR) by immunohistochemistry using standard procedures.
Exome-Seq analysis
DNA from 29 DCIS samples and their paired normal breast tissue samples (n = 58 samples) 
were purified using the DNeasy Blood and Tissue Kit (Qiagen). Only DNA samples with 
260/280 ratios greater than 2.0 were processed for library construction using the SPRIworks 
Fragment Library Kit I (Beckman Coulter). Four libraries were pooled together and 
processed for exome capture using the NimbleGen SeqCap EZ Human Exome Library v3.0 
(HG19, Roche), covering more than 23,000 genes and ~64 Mbp, 76-nt paired-end 
sequencing was performed using an Illumina HiSeq2000 platform at our Department's NGS 
Facility. Image analysis, base-calling, and error calibration were performed using Illumina's 
Genome analysis pipeline. Sequencing was performed reaching an average depth of 40× per 
sample. Sequenced 76-bp tags were aligned against the human reference genome (hg19) 
using BWA v0.7.3 and marked for duplicates using Picard v1.88 (http://
picard.sourceforge.net/). Recalibration of base quality and indel realignment was performed 
using the GATK v2.4 (20). Subsequently, single-nucleotide variants (SNV) were identified 
using MuTect v1.1.4 (21). Identified variants were annotated using ANNOVAR (22), 
filtered by functional consequence, and only nonsynonymous and splicing variants were 
selected. In addition, we used Control-FREEC software to detect copy number alterations 
and LOH regions in DCIS samples on the basis of Exome-Seq data (23).
RRBS analysis
We analyzed by RRBS a total of 5 normal breast epithelial samples and 24 DCIS samples. 
DNA libraries were prepared for RRBS at the MDACC's DNA Methylation Core Facility 
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and subjected to next-generation sequencing (NGS). Short read sequences were mapped to 
the human reference genome 19 by Bismark, a program to map bisulfate-treated sequencing 
reads to a genome of interest and perform methylation calls in a single step (24). Raw 
datasets have been submitted to NCBI GEO database with accession number GSE69994. 
Promoter regions were calculated on the basis of RefSeq gene annotations, such that the 
region starts 2-kb upstream of the annotated transcription start site and extends to 500 
downstream of the transcription start site (TSS). CpG islands were downloaded from UCSC 
genome annotation database assembled by NCBI (hg19). CpG shores were defined as 2,000-
bp flanking regions on upstream and downstream of a given CGI. To identify differentially 
methylated sites, first we filtered samples on the basis of read coverage ≥ 20. And the 
significant differentially methylated CpGi (DMC) sites were identified when the difference 
of methylation percentages between normal breast epithelia and DCIS were greater than 
0.25 and q < 0.01.
RNA-Seq analysis
RNA was isolated and purified using TRIzol reagent (Life Technologies) and RNeasy mini 
kit (Qiagen). RNA concentration and integrity were measured on an Agilent 2100 
Bioanalyzer (Agilent Technologies). Only RNA samples with RNA integrity values (RIN) 
above 8.0 were considered for subsequent analysis. mRNA from normal breast epithelial 
samples and DCIS samples were processed for directional mRNA-Seq library construction 
using the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre) according to the 
manufacturer's protocol. We performed 76-nt paired-end sequencing using an Illumina 
HiSeq2000 platform and obtained about 40 million tags per sample. The short sequenced 
reads were mapped to the human reference genome (hg19) by the splice junction aligner 
TopHat (25). We used several R/Bioconductor packages to accurately calculate the gene 
expression abundance at the whole-genome level using the aligned records (BAM files) and 
to identify differentially expressed genes between normal and DCIS samples. Briefly, the 
number of reads mapped to each gene on the basis of the UCSC.hg19.KnownGene database 
were counted, reported, and annotated using the GenomicFeatures, Rsamtools, and 
org.Hs.eg.db packages. Raw datasets have been submitted to NCBI GEO database with 
accession number GSE69994. To identify differentially expressed genes between normal 
breast epithelium and DCIS samples, we used the edgeR-test on the basis of the normalized 
number of reads mapped to each gene (26).
Pathway-based analysis was performed using the PARADIGM software at the Five3 
Genomics server (default options; discretization bounds of 33%) on the basis of the 
normalized gene expression profiles of the deregulated transcripts between normal and 
DCIS samples [false discovery rate (FDR) < 0.01; log fold change (FC) ≥ ±1] expressed in 
log2 counts per million (27). PARADIGM produces a data matrix of integrated pathway 
activities (IPA), this data matrix was used in place of the mRNA expression profiles to 
identify the topmost variable IPAs among samples. Heatmap visualization of differentially 
expressed transcripts and IPAs were done with the MultiExperiment Viewer software (MeV 
v4.9; ref. 28). Intrinsic subtype classification of DCIS samples into luminal-like, basal-like, 
ERBB2-enriched, and normal-like groups was performed using the 50-gene (PAM50) 
predictor bioclassifier R script (29). We used the ESTIMATE algorithm (Estimation of 
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STromal and Immune cells in Malignant Tumors using Expression data) to infer the immune 
and stromal components from each DCIS sample (30).
Bioinformatic analysis of the The Cancer Genome Atlas-BRCA dataset
To perform a comparative analysis of the mutational, gene expression, methylation, and 
pathway activities profiles identified in DCIS with invasive stages, we analyzed invasive 
breast cancer (IBC) datasets obtained from the The Cancer Genome Atlas (TCGA)-BRCA 
project (31). The clinical (including PAM50 subtypes from RNAseq) and preprocessed data 
(IBC gene-level mutation, IBC gene expression Illumina HiSeq, IBC DNA methylation 
450K and IBC Paradigm RNAseq + CNV profiles) were retrieved from the Cancer 
Genomics Browser (https://genome-cancer.soe.ucsc.edu/) and cBioPortal (http://
www.cbioportal.org/). Data integration and visualization were done with R and MeV 
software, respectively.
Results and Discussion
Fresh-frozen pure DCIS samples are extremely difficult to obtain, as all tumor materials are 
submitted for routine histopathologic evaluation with formalin fixation and paraffin 
embedding. Only cases with available frozen tissue samples are usually those from large 
palpable DCIS cases, which tend to be HG-DCIS. Nevertheless, we were able to gather from 
our Institution's breast tumor bank a group of fresh-frozen "pure" HG-DCIS samples (i.e., 
with no evidence of invasion in the same breast) and matching normal pairs and subjected 
them to a thorough characterization involving whole Exome-Seq, RRBS, and RNA-Seq. We 
also generated RNA-Seq and RRBS data from breast epithelial organoids obtained from 
normal mammoplasty specimens for identification of differentially expressed genes and 
differential methylated genes between normal and DCIS lesions.
Significantly mutated genes and DNA copy number variations in DCIS
Exome-Seq data on 29 pure DCIS normal matched pairs indicated a median of 75% targeted 
genome loci having at least 40× coverage. We detected 2,908 single-base substitutions, 
including 1,324 nonsynonymous (missense) SNVs, 46 stop gain, 2 stop loss, 16 mutations at 
splicing sites, 151 noncoding RNA (ncRNA) mutations, and 1,369 SNVs encoded 
synonymous (silent) mutations (Fig. 1A; Supplementary Table S2). Almost 50% of these 
mutations were C>T:G>A transitions in agreement with the previously described most 
prevalent mutation-type signature in breast cancer (Fig. 1A; ref. 32). We also detected 24 
frameshift deletions, 10 frameshift insertions, and 43 non-frameshift deletion/insertion 
events. Every single DCIS displayed a significant number of mutations. The total mutation 
rate was 1.61 mutations per Mbp on average with a range of 0.8 to 3.8 mutations per Mbp 
(Fig. 1B), indicating that some DCISs have quite higher mutation rates than others. We 
identified somatic mutations affecting at least 10 genes reported as mutated at a ≥2% rate in 
IBC (33). In total, 18 of 29 HG-DCIS cases (62%) displayed mutations affecting one or 
combinations of targets described as cancer driver genes or potential drivers. Among these, 
we detected mutations affecting PIK3CA (21%), TP53 (17%), GATA3 (7%), MLL3 (7%) and 
single cases of mutations affecting CDH1, MAP2K4, TBX3, NF1, ATM, and ARID1A (Fig. 
1B). The comparative frequency of mutations of these genes in pure DCIS and the TCGA 
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database on IBC (n = 976 cases as per September 2014) is shown in Fig. 1C. Similarly to 
IBC previous gene mutation data (31, 33), the most frequently mutated genes are PIK3CA (6 
cases; 4 of them affecting ER/PR-positive cases) and TP53 (5 cases; 4 of them affecting 
ER/PR-negative cases). Only one case displayed mutations in both genes. Interestingly, 
several genes reported as mutated in IBC, such as MAP3K1, PTEN, AKT1, RUNX1, RB1, 
and various others so far, have not been detected mutated in DCIS, suggesting that perhaps 
some of these mutations may be associated with postinvasion events; however, our sample 
number is still limited. In summary, we observed that 100% of pure HG-DCIS display 
numerous somatic mutations, but only a subgroup display mutations affecting cancer driver 
genes or potential drivers. Nevertheless, the mutational profile in pure HG-DCIS is 
extremely similar to that observed at invasive stages with only a moderate lower frequency 
of mutation for cancer driver genes. As we performed RNA-Seq in parallel, the identified 
mutations were validated by allele-specific RNA-Seq data.
Somatic copy number variations (CNV) were estimated using Exome-Seq data to predict 
regions of genomic alterations such as amplification, gains, and losses (23). Figure 1D 
summarizes the overall frequency of DNA gains/losses affecting all chromosome arms 
among DCIS samples. The profile of copy number changes across the genome in HG-DCIS 
is practically identical to profiles reported in invasive breast lesions (34) and is in agreement 
with early observations using comparative genome hybridization (CGH) approaches (35). In 
our approach, however, we were able to define with more precision the genomic regions 
spanning the CNV (Supplementary Table S2). The most common regions of increased DNA 
copy number include chr1q, chr8q, chr17q, and chr20q and regions of common copy 
number loss include regions chr8p, chr11q, chr17p, and chr22q (Fig. 1D; Supplementary 
Fig. S1 and Supplementary Table S2). Regions of potential focal amplification were also 
identified, including ERBB2, VEGFA, MYC, AURKA, MDM2, FGFR1, and CCND1 (Fig. 1B 
and Supplementary Table S2).
Among the most important conclusions of the CNV analysis is that 83% (24 of 29) of DCIS 
lesions displayed evidence of large chromosomal alterations; only in 5 samples (T9, T15, 
T28, T30, and T31), large chromosomal copy number changes were not detected 
(Supplementary Table S2). Interestingly, multiple cases (T2, T4, T5, T10, T13, T16, T22, 
and T24) displayed significantly large chromosomal copy number alterations but no 
mutations in known cancer driver genes, whereas 16 of 18 cases (89%) with mutations in 
cancer driver genes all show significant chromosomal copy number alterations (Fig. 1B; 
Supplementary Table S2). Importantly, in only 3 of 29 (10%) HG-DCIS (T9, T15, T28), no 
large chromosomal abnormalities or mutations in putative cancer driver genes were 
detected. Nevertheless our findings also suggest that large chromosomal copy number 
alterations (trisomies, monosomies, large chromosomal duplications, and deletions) occur 
early in tumor progression, perhaps preceding the selection of alleles with mutations in 
driver genes.
Gene expression analysis of coding RNAs
Whole-transcriptome unsupervised analysis from RNA-Seq data demonstrates a clear 
segregation of normal breast epithelium and DCIS samples on the basis of similarity 
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distances (measured in leading logFC) from dimension 1 in a multidimensional scaling plot 
(MDS; Fig. 2A). More importantly, DCIS samples were clustered into two subgroups 
(cluster 1 or DCIS-C1 and cluster 2 or DCIS-C2) according to the positive and negative 
distances from MDS dimension 2.
We observed that the ER/PR status determined by immunohistochemistry and their intrinsic 
subtypes predicted by using the 50-gene PAM50 model (29) were significantly associated 
with each identified DCIS cluster (P < 0.001). Sixty-seven percent of the cases in DCIS-C1 
were ER/PR double negative and basal-like or ERBB2+ with high proliferative scores. On 
the other hand, 100% of the cases in DCIS-C2 were ER/PR double positive, luminal-like 
with low/moderate proliferative scores (Fig. 2B).
Statistical analysis of RNA-Seq data revealed 5,985 transcripts differentially expressed 
between normal and DCIS samples (FDR < 0.01; logFC ≥ ±1), 95% were coding RNAs and 
5% were ncRNAs. Among the deregulated genes, 885 were differentially expressed between 
both DCIS clusters (FDR < 0.01; logFC ≥ ±1; Supplementary Table S3). To identify 
bioprocesses that differentiate DCIS-C1 from the DCIS-C2, we performed functional 
enrichment and pathway activity analyses. Gene ontology (GO) analysis of deregulated 
transcripts between DCIS clusters revealed specific functional modules characteristic for 
each of both subgroups: a functional module strongly related to immune (P < 1.46E−35) and 
inflammatory (P < 6.4E−19) responses clearly associated to the DCIS-C1 group and a 
module related with response to steroid hormones (P < 9.1E−4) associated to the DCIS-C2 
group (Fig. 2C and Supplementary Fig. S2). In addition, functional annotation analysis 
identified "T-cell differentiation", "B-cell activation", "angiogenesis," "negative regulation 
of apoptosis," and "ECM remodeling" to be highly associated with DCIS-C1 -modulated 
genes. Given the aforementioned strong association with immune-related themes, we 
performed a blind evaluation of lymphocytic infiltrates on H&E sections of all DCIS 
samples determining iTIL and sTIL scores. Supporting the GO and functional annotation 
observations, DCIS-C1 samples showed a significantly higher number of iTILs (P < 0.01) 
than the DCIS-C2 counterparts. Similarly, a gene expression signature–based method known 
as ESTIMATE (30) predicted higher immune scores on DCIS-C1 versus DCIS-C2 (P < 
0.001; Fig. 2D).
Further analysis of the behavior of the 885 deregulated transcripts that discriminate both 
DCIS clusters within the TCGA breast cancer dataset demonstrated that a large number of 
genes (~80%)identified as upregulated in the DCIS-C1 group remained upregulated in basal-
like and ERBB2+ breast cancers compared with the luminal A/B subtypes (Fig. 2E). This is 
in itself very significant, and similarly to the above described mutational and CNV analyses, 
it indicates that most of the gene expression changes characteristic of IBC are already 
present at the pure DCIS (preinvasive) stage.
Pathway-based representation analysis (PARADIGM; ref. 27) of deregulated transcripts 
identified a plethora of signaling pathways that differ in their activity between normal and 
DCIS samples, such as AP1, TNF, TP53, FOXM1, MYB, and E2F1/DP1 pathways (Fig. 
3A; Supplementary Table S3). It was striking to observe that the TP53 signaling pathway 
was found deactivated in all DCIS samples analyzed regardless of TP53 mutation status, 
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ER/PR expression status or intrinsic subtype when compared with normal epithelium (Fig. 
3B). Since on the basis of mutational evidence is currently believed that TP53 inactivation is 
mostly a feature of the basal-like intrinsic subtype (31, 33), we were surprised by our 
finding, thus we decided to perform a pathway-based analysis focused on the TP53 pathway 
exclusively in the existing TCGA IBC dataset. Interestingly, PARADIGM analysis based on 
TCGA-BRCA RNA-Seq and CNV profiles predict that TP53 pathway inactivation is a 
common theme affecting well above 85% of breast cancers regardless of intrinsic subtypes 
(and as consequence also regardless of TP53 mutation status; Supplementary Fig. S3). 
Nevertheless, this novel information on TP53 pathway inactivation in most breast cancers 
should be taken with caution and requires further validation.
In the DCIS-C2 cases, the activity of the E2/ERa pathway was the predominant signature 
(Supplementary Fig. S2), whereas in the DCIS-C1 subgroup, the HES1 and HIF1A/ARNT 
pathways were more frequently activated. Interestingly, the HIF1A/ARNT was previously 
identified as one of the key regulatory features associated with basal-like carcinomas (31).
More importantly, PARADIGM analysis identified that 80% of DCIS-C1 cases showed 
activity of Treg cells (CD4+/CD25+/FOXP3+) and CTLA4+/CD86+ complexes (Fig. 3C). 
These results are revealing, as a growing body of evidence indicates that the outcome of an 
immune response toward a tumor is largely determined by the specific characteristics of the 
infiltrating lymphocytes. A tumor-directed immune response involving cytolytic CD8+ T 
cells, T-helper 1 cells (Th1), and natural killer (NK) cells appears to protect against tumor 
development and progression, whereas activation of humoral immunity involving B cells 
and/or Th2 response appears associated to protumorigenic phenotypes (36). Suppression of 
antitumor immune response by inducing T-cell anergy due Th2-polarized activity and/or 
expansion of Treg cells (CD4+CD25+FOXP3+) with a subsequent loss of T-cell–mediated 
cytotoxicity, together with the development of angiogenesis and tissue remodeling could be 
instrumental for promoting the progression of HG-DCIS to the infiltrating stages. Recently, 
Kristensen and colleagues (37) suggested that the perturbation in the immune response and 
IL signaling (IL4, IL6, IL12, and IL23) can lead to classification of IBC subclasses with 
prognostic value. Patients who have basal-like breast carcinomas are characterized by high 
expression of protumorigenic Th2/humoral-related genes and a low Th1/Th2 ratio. In 
addition, the immune response and IL signaling identified in IBC appears also prominent in 
DCIS (37). Importantly, the IPA described in our study indicates that DCIS-C1 lesions are 
characterized by a tumor-associated immunosuppressive phenotype, suggesting a 
protumorigenic polarization of the immune response. In other words, DCIS-C1 lesions bear 
all the immunomodulatory characteristic of invasive breast lesions, thus indicating that the 
host immune defenses (tumor rejection responses) have been or are in the process of being 
defeated.
Gene expression analysis of noncoding RNAs
RNA-Seq analysis allowed us to identify 193 long noncoding RNAs (lncRNA) as 
differentially expressed between normal and DCIS samples (P < 0.01, FDR < 0.01), 127 of 
which were antisense RNAs and 66 were long intergenic noncoding RNAs (lincRNA; Fig. 
4A and B). Eighty-seven percent of the identified lncRNAs (168 of 193) were upregulated in 
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DCIS (Supplementary Table S4). Interestingly, 46 of the 127 antisense RNAs and 18 of the 
66 lincRNAs have been recently identified as potentially relevant in breast cancer (38). The 
Genomic Regions Enrichment of Annotations Tool (GREAT) resource was used to evaluate 
the correlation between deregulated lncRNAs and their neighboring genes (39). We found 
that 52% of the mRNA genes in the vicinity of the affected lncRNAs were also deregulated 
(Supplementary Table S4), and most of them (80%) showed a positive association with the 
expression of the lncRNAs, which would indicate that deregulation of cis-acting lncRNA 
prevails in DCIS. Among the deregulated lnRNAs in DCIS, we found HOTAIR (HOX 
transcript antisense RNA; logFC = +5.03; FDR = 1.92E−8) and HOTAIRM1 (HOXA 
transcript antisense RNA myeloid–specific 1; logFC = −1.90; FDR = 8.63E−7; Fig. 4C). 
HOTAIR and HOTAIRM1 expression levels were positively correlated with the expression 
of their adjacent HOXC (located at chr12q13.13) and HOXA (located at chr7q15.2) gene 
clusters, respectively (Fig. 4D). Recent studies have shown that lncRNAs can be associated 
with enhancer regions, leading to increased activity of neighboring genes (40). One of the 
best-known lncRNAs, HOTAIR, found significantly upregulated in DCIS-C1 lesions, was 
suggested to promote breast cancer metastasis and shown to be pervasively overexpressed in 
most human cancers when tumor tissue was compared with adjacent noncancerous tissue 
(41). HOTAIR interacts with and recruits the Polycomb-repressive complex 2 (PRC2) and 
regulates chromosome occupancy of EZH2 (a subunit of PRC2), which leads to histone H3 
lysine 27 trimethylation of the HOXD locus and subsequent silencing of this gene cluster. 
On the other hand, HOTAIRM1, found significantly downregulated in many DCIS lesions 
(particularly DCIS-C1), was shown to play a role in the regulation of gene expression during 
retinoic acid–induced myeloid differentiation preventing the induction of HOXA genes (42). 
Mechanistically, our data indicate that HOTAIR and HOTAIRM1 may act by modulating 
HOX gene expression in trans and cis during early stages of breast cancer progression. This 
is the first study demonstrating that these lncRNAs are deregulated "early" at preinvasive 
stages of breast cancer progression. The remaining lncRNAs (LINC00277, LINC00861, 
LINC00578, LINC00426, and others shown in Supplementary Table S4) would constitute a 
novel group of lncRNAs deregulated in the transition normal DCIS.
In addition, we were able to identify 36 differentially expressed pri/pre-miRNAs among the 
deregulated noncoding transcripts between normal and DCIS as well. We detected MIR3606 
(logFC = +6.58), MIR4728 (logFC = +4.25), and MIR503HG (logFC = +2.91) among the 
most upmodulated small noncoding RNAs in DCIS samples. Interestingly, MIR4728 was 
specifically upmodulated in DCIS-C1 samples (logFC = +2.28). MIR4728 gene is located at 
chr17q12 and encoded within intron 24 of the ERBB2 gene (43). Recently, Newie and 
colleagues demonstrated that ERBB2 amplification might lead to ESR1 downregulation 
through internal seed interaction with miR-4728-3p in breast cancer cells (44). We 
corroborate this observation identifying a positive correlation between ERBB2 and MIR4728 
expression (r = 0.90; P < 0.01) in DCIS samples in agreement with the CNV data.
On the other hand, MIR4260 (logFC = −4.62), MIRNA221 (logFC = −3.55), MIR22/
MIR22HG (logFC = −2.34), MIR3661 (logFC = −2.07), and MIR17HG (logFC = −1.94), 
among others, were detected as downmodulated in DCIS samples. The human MIR22 gene 
is located in a minimal LOH region on chromosome 17 close to TP53. MIR22 has been 
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reported to be downregulated in hepatocellular, lung, colorectal, ovarian and breast cancer, 
acting as a tumor suppressor (45). Furthermore, MIR22 overexpression induces growth 
suppression and senescence-like phenotypes in human breast epithelial and breast cancer 
cells (46). MIR17HG is the host gene for the MIR17–20 cluster (a group of at least six 
miRNAs) located at 13q31 that function as a tumor suppressor in human breast cancer by 
decreasing AIB1 and cyclin D1 expression (47). The MIR17–20 cluster is known to inhibit 
breast cancer cellular proliferation through G1–S cell-cycle arrest (48). Our study suggests 
that gain and loss of expression of key regulatory miRNAs in normal breast epithelium 
might constitute important early procarcinogenic events conducive to overcome the barrier 
imposed by senescence and limited cell proliferation. However, further studies on the 
profiling of the mature miRNAs in normal and DCIS samples are needed to corroborate the 
aforementioned observations.
DNA methylation analysis
RRBS data analysis coupled with RNA-Seq profiling allowed us to identify the most 
relevant methylation events associated to the development of DCIS lesions. We identified 
1,103 DMCs between normal breast epithelia and DCIS samples (Supplementary Table S5), 
mapping at distal (8% at −4 kb to −2 kb relative to TSS), proximal promoter regions (56% at 
−2 kb to +500 bp) or the gene body (36% at +500 to +2 kb) of 311 loci (Fig. 5A). Among 
these 1,103 DMC, 1,029 were hypermethylated and 74 were hypomethylated CpGi sites in 
DCIS samples. Functional enrichment analysis of the hypermethylated regions in DCIS 
identified "regulation of transcription/RNA pol II activity," "cell fate commitment/
morphogenesis," and "regulation of cell proliferation and differentiation" as the predominant 
associated biologic processes (Fig. 5B). Furthermore, we identified 137 DMC for which 
mRNA abundance was inversely correlated in DCIS samples (Supplementary Table S5). 
Sixteen genes were highly hypermethylated and downmodulated in DCIS compared with 
normal epithelium (Fig. 5C). Some of the most hypermethylated CpGi regions were located 
at the promoters of three SOX family members (SOX10, 15, and 17) and the HOXA5 gene. 
SOX10, SOX15, and SOX17 are novel HMG box–containing tumor suppressors involved in 
a variety of developmental processes that can act as antagonists to the Wnt/β-catenin 
signaling pathway (49–51). These three SOX genes were systematically hypermethylated 
and transcriptionally downregulated in almost all DCIS samples compared with normal 
samples. In agreement with these findings, gene expression analysis of these SOX genes in 
the TCGA dataset showed a significant downmodulation in IBC compared with normal 
samples (Supplementary Fig. S4). In a recent study, it was shown that the SOX10 protein is 
predominantly expressed in basal-like breast carcinomas compared with the other subtypes 
(52). However, TCGA data analysis clearly showed that SOX10 was downmodulated in 
luminal-like and ERBB2+ breast cancer subtypes compared with normal tissue samples 
(Supplementary Fig. S4). Fu and colleagues (50) demonstrated that silencing of SOX17 due 
to promoter hypermethylation is frequent in invasive carcinomas and may contribute to 
aberrant activation of Wnt signaling in breast cancer. This evidence raises the possibility 
that hypermethylation of specific SOX family members could constitute common important 
epigenetic phenomena occurring at early stages of breast cancer development that deserves 
further study.
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Interestingly, in our dataset, HOXA5 hypermethylation was more frequently associated with 
the DCIS-C1 group, characterized by the presence of tumors with basal-like/ERBB2 
intrinsic subtypes (Fig. 5D). TP53 gene expression has been shown to be under the control 
of HOXA5 in breast cancer cells (53). Reduced HOXA5 protein levels correlate with the 
lack of p53 expression, supporting the concept that HOXA5 may act as a tumor suppressor 
via activation of p53 expression. HOXA5 has also been shown to be a strong positive 
regulator of PR (54). It is also important to note that 4 of 5 cases with TP53 non-
synonymous mutations were detected in ER/PR double negative tumors from the DCIS-C1 
group (T3, T7, T26, and T29). Overall, these data suggest that TP53 mutation and HOXA5 
hypermethylation could constitute early events during breast cancer progression that can 
cooperate to inactivate the TP53 pathway in more prone to progress DCIS lesions. In 
addition our pathway-based analysis indicated that TP53 pathway inactivation is an 
extremely common feature in practically all HG-DCIS lesions and HOXA5 methylation 
could be one of the more relevant causative mechanisms. CpGi methylation and expression 
analysis from the TCGA breast cancer dataset demonstrated that HOXA5 hypermethylation 
and downregulation can be also identified and is common in more advanced stages of breast 
cancer progression (Fig. 5E and F).
Concluding Remarks
Comprehensive characterization of pure HG-DCIS lesions at the genome, transcriptome, and 
methylome levels allowed us to identify the most relevant changes occurring at a 
preinvasive stage of breast cancer progression. A comparison of the mutation and 
chromosomal copy number alteration profiles identified in these pure in situ lesions with 
previous observations reported by the TCGA study on IBC, revealing expected similarities 
with IBC (e.g., PIK3CA, TP53, GATA3). However, it was striking to observe that practically 
all known major genomic abnormalities are already present at preinvasive stages at high 
frequency mutation rates and 83% of lesions displaying very large copy number 
chromosomal alterations. In only 10% of lesions we did not detect large chromosomal 
changes or mutations in so-called cancer driver genes. More importantly, at the 
transcriptional level, pathway-based analysis pointed to TP53 pathway inactivation as 
extremely common in DCIS regardless of tumor intrinsic subtype. We also observed that 
deregulation of genes associated with the suppression of the antitumor immune response are 
hallmarks of a HG-DCIS subgroup (highly proliferative basal-like or ERBB2+ tumors), 
displaying profiles very similar to those found at invasive and metastatic stages. In addition, 
we identified novel and relevant regulatory circuits significantly deregulated in DCIS that 
were not previously reported and that involve coding and noncoding transcripts (e.g., 
HOTAIR, HOTAIRM1). Our comprehensive catalogue of differentially expressed genes is 
also consistent with the existence of the most common breast cancer subtypes, but now we 
show that these important and complex epigenetic changes, such as hypermethylation of 
HOXA5 and specific SOX genes, are already operating at the in situ stage. Our findings 
clearly indicate that a subgroup of HG-DCIS lesions can be identified displaying more 
aggressive molecular profiles, more importantly however is that most, if not all, HG-DCIS 
lesions displayed profiles indistinguishable from IBC.
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Figure 1. 
Mutations and copy number alterations in DCIS samples. A, types of single-base 
substitutions and InDels identified by Exome-Seq analysis. B, driver and co-driver 
mutations in DCIS samples. Each column represents one DCIS case and each row represents 
the number of mutations in each gene per tumor. Blue squares, + mutation. Genes shown 
with an asterisk are rarely mutated in IBC (≤2%); however, they are noted as possible co-
drivers events, as they are found either in the SANGER Cancer Gene Census database or 
have significant potentially carcinogenic biological functions. C, comparative frequency of 
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mutations of driver/co-driver mutations in pure DCIS (red bars) and the TCGA database on 
IBC (blue bars). D, CNVs among DCIS samples. Chromosomal gains (red, up) and losses 
(green, down) as percentage of occurrence in the respective region are indicated.
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Figure 2. 
Transcriptome analysis of normal and DCIS samples. A, multidimensional scaling plot 
showing the distance of each sample from each other determined by their leading logFC. 
The leading logFC is a distance metric that represents the average (root mean square) of the 
largest absolute logFC between each pair of samples. B, prediction of DCIS intrinsic 
subtypes based on the PAM50 gene model based on RNA-Seq profiles. All normal samples 
(not included in the heatmap) were classified as the normal-like subtype. C, functional 
enrichment analysis of the differentially expressed genes between DCIS clusters. D, box and 
whisker plots display increased iTIL (left) and immune scores determined by the 
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ESTIMATE (30) algorithm (right) for the DCIS-C1 group compared with DCIS-C2 group 
and normal samples. E, heatmap of DCIS-C1 and DCIS-C2 differentially expressed 
transcripts among the IBC subtypes obtained from the TCGA breast cancer database.
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Figure 3. 
Pathway activities analysis in DCIS samples versus normal mammary epithelium. A, 
PARADIGM inferences of the most variable integrated pathway activities using the 
normalized gene expression profiles of the deregulated transcripts between normal and 
DCIS samples. B, TP53 pathway activity was found systematically deactivated in both 
DCIS groups compared with normal epithelium (P < 0.001). C, PARADIGM analysis 
identified increased activities of Treg cells (CD4+/CD25+/FOXP3+) and CTLA4+/CD86+ 
complexes in DCIS-C1 compared with DCIS-C2 samples (P < 0.01).
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Figure 4. 
Gene expression profile of deregulated lncRNAs. A, pie chart displaying the types of 
lncRNAs differentially expressed between normal and DCIS samples. B, heatmap of 
deregulated lncRNAs where black lines on the right indicate potentially relevant transcripts 
in IBC as was determined by Su and colleagues (38). C, box and whisker plots representing 
HOTAIR and HOTAIRM1 expression levels among normal and DCIS samples. D, 
transcriptomic coexpression analysis using HOTAIR and HOTAIRM1 as templates identified 
significant positive correlations with the expression of their neighboring HOXC (located at 
chr12q13.13) and HOXA (located at chr7q15.2) gene clusters, respectively (r > 0.7 and P < 
0.0001).
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Figure 5. 
Analysis of differentially methylated CpGi among normal and DCIS samples determined by 
RRBS. A, distribution of 1,103 differentially methylated CpGi regions between normal and 
DCIS samples mapping at distal (−4 kb to −2 kb relative to TSS), proximal promoter regions 
(−2 kb to +500 bp), or the gene body (+500 to +2 kb). B, functional enrichment analysis of 
differentially methylated CpGi regions. C, heatmap of CpGi hypermethylated and 
downregulated genes in DCIS samples. D, HOXA5 CpGi methylation profile in normal and 
DCIS groups in a promoter region spanning from −285 to 560 bp relative to TSS. HOXA5 
methylation (E) and expression profiles (F) among normal and IBC from the TCGA breast 
cancer dataset.
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